跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 68 条关于
“nrSPMS”
全部
68
临床试验
56
药物
1
机构
0
资讯
11
去年
Tolebrutinib Receives FDA Breakthrough Therapy Designation for Non-Relapsing Secondary Progressive Multiple Sclerosis
去年
Sanofi's Tolebrutinib Shows Promise in Non-Relapsing Secondary Progressive MS
2年前
Tolebrutinib Shows Promise in Slowing Disability Progression in Non-Relapsing Secondary Progressive MS
去年
Key Neurology Advances of 2024: From Novel Therapies to Trial Innovations
去年
FDA Halts PepGen's DMD Trial, Sanofi's MS Drug Tolebrutinib Gains Breakthrough Status, and Sevasemten Shows Promise in Becker Muscular Dystrophy
去年
Breakthrough Year in Multiple Sclerosis Research: Key Advances and Treatment Milestones in 2024
去年
Sanofi's Q3 Sales Surge 15.7% Driven by Vaccines and Dupixent; 2024 EPS Guidance Raised
去年
FDA Roundup: Approvals, Breakthrough Designations, and Clinical Holds in Neurology and Rare Diseases
去年
Multiple Sclerosis Pipeline Shows Promise with Novel Therapies in Development
去年
Dr. Reddy's Siponimod Tablets Recommended for Marketing Approval in India for SPMS Treatment
第 1 页,共 2 页
上一页
下一页